Evolent Health, Inc. 8K

Evolent Health filed an 8-K to announce its second quarter 2026 results, raise 2026 guidance, outline a strong 2027 growth outlook, and disclose two material partnership expansions including a major oncology contract expected to generate about $300 million in annualized revenue.

Evolent Health, Inc. reported its financial results for the quarter ended June 30, 2026, showing strong year-over-year revenue growth to $652.5 million but a GAAP net loss of $28.4 million, alongside updated full-year 2026 guidance for revenue of $2.6–$2.7 billion and Adjusted EBITDA of $120–$135 million. Management highlighted expectations for more than 25% revenue growth in 2027 and Adjusted EBITDA at or above $150 million driven by improved Performance Suite margins and cost reductions, and disclosed two new partnership expansions: a large Oncology Performance Suite contract expected to launch by December 2026 covering about 1.5 million lives and generating roughly $300 million in annualized revenue, and a smaller Specialty Technology & Services Suite expansion with an existing Blues plan customer expected to add under $5 million in annualized revenue. The company also discussed ongoing industry headwinds, including Medicaid and client membership attrition, its AI-led operational model, planned capitalized software development spending of $25–$30 million in 2026, and its intent to evaluate targeted debt reduction initiatives to enhance financial flexibility.

Filing Facts

CIK

1628908

Ticker

-

Form

8K

Source Type

sec

Accession

0001628908-26-000084

Alert Tier

7